Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Infection and Chemotherapy
Published in: Journal of Infection and Chemotherapy 3/2012

01-06-2012 | Case Report

Tuberculous hilar lymphadenopathy progressing after isoniazid administration

Author: Shuichi Yano

Published in: Journal of Infection and Chemotherapy | Issue 3/2012

Login to get access

Abstract

Right hilar lymphadenopathy was the only radiologic finding in an immunocompetent 19-year-old man with a positive whole blood interferon-γ enzyme-linked immunosorbent test (QuantiFERON-TB-2G). Because his initial treating physician did not notice the lung lesion on chest radiography, isoniazid (INH) monotherapy was begun with subsequent progression of the lymphadenopathy. We must take into consideration even hilar lymphadenopathy in patients with tuberculosis (TB) disease without detectable Mycobacterium (M.) tuberculosis organisms, because INH monotherapy may result in progression of the TB lesion.
Literature
1.
Mc Adams HP. Radiologic manifestations of pulmonary tuberculosis. Radiol Clin North Am. 1995;33:655–75.
2.
Mona R, William B. Tuberculosis in children. In: William NR, Stuart MG, editors. Tuberculosis. 2nd ed. USA: Lippincott Williams & Wilkins; 2004. p. 615–6.
3.
Stanberry SD. Tuberculosis in infants and children. J Thorac Imaging. 1990;5:17–27.CrossRef
4.
Leung AN. Primary tuberculosis in childhood: radiographic manifestations. Radiology. 1992;182:87–91.PubMed
5.
Mazurek GH, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR. 2005;54(RR15):49–55.PubMed
6.
Khan EA, Starke JR. Diagnosis of tuberculosis in children. Increased need for better methods. Emerg Infect Dis. 1995;1:115.PubMedCrossRef
7.
Jeffrey RS. Tuberculosis in infants and children. In: Schlossberg D, editor. Tuberculosis and nontuberculous mycobacterial infections. 5th edn. USA: WB Saunders Company; 2006. p. 365.
8.
Charles LD. Tuberculosis latency in humans. In: Schlossberg D, editor. Tuberculosis and nontuberculous mycobacterial infections. 5th edn. USA: WB Saunders Company; 2006. p. 86.
9.
Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, Werely C, van Helden PD, Maritz JS. The influence of human N-acetyltransferase genotype on the early bacteriocidal activity of isoniazid. Clin Infect Dis. 2004;39:1425–30.PubMedCrossRef
10.
Isoniazid. In: Kucers A, Crowe SM, Grayson MI. The use of antibiotics. 5th edn. Boston: Butterworth-Heineman; 1997. p. 1179-1210.
Metadata
Title
Tuberculous hilar lymphadenopathy progressing after isoniazid administration
Author
Shuichi Yano
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 3/2012
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-011-0328-9

Other articles of this Issue 3/2012

Journal of Infection and Chemotherapy 3/2012 Go to the issue

Original Article

Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitalium

Original Article

Enhancement of interleukin-8-induced chemotactic response and reactive oxygen species production in HL-60 cells expressing CXCR1

Original Article

Experimental application of a synthetic luminescent substrate assay using endotoxin-specific limulus amebocyte lysate to human blood

Note

Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study

Erratum

Erratum to: Association between the number of blood cultures and appropriateness of care for suspected bacteremic urinary tract infection in the elderly

Original Article

Clinical characteristics of healthcare-associated pneumonia in a public hospital in a metropolitan area of Japan
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits